The biomarkers consortium: On the critical path of drug discovery

被引:41
作者
Altar, C. A. [1 ]
机构
[1] Biomarkers Consortium, Fdn Natl Inst Hlth, Bethesda, MD 20892 USA
关键词
D O I
10.1038/sj.clpt.6100471
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent advances in science have provided a variety of genetic, genomic, and protein-based methods to treat human diseases.(1,2) These advances, and equally great strides in in vivo imaging(3-7) and methods of tissue collection, have created an unprecedented opportunity to discover and develop biological markers of human disease. A biomarker is defined(8,9) as a molecular, biological, or physical characteristic that indicates a specific physiologic state (see Table 1 for definitions). It is used in clinical practice to identify risk for disease, diagnose disease and its severity, guide intervention strategies, and monitor patient responses to therapy. When used in a clinical research setting, biomarkers may predict whether a drug or other intervention is safe and effective(10) in a shorter time and at lower cost than clinical outcomes studies. For these and other reasons, including the ability to stratify patient groups based on objective criteria, biomarkers help promote regulatory approval of new therapeutic entities by pharmaceutical, biological, and device development teams.
引用
收藏
页码:361 / 364
页数:4
相关论文
共 20 条
  • [1] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [2] Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program -: Comparative evaluation of three assays
    Blueher, Matthias
    Fasshauer, Mathias
    Brennan, Aoife M.
    Kralisch, Susan
    Kelesidis, Theodoros
    Williams, Catherine J.
    Kratzsch, Juergen
    Mantzoros, Christos S.
    [J]. DIABETES CARE, 2007, 30 (02) : 280 - 285
  • [3] Daniels R., 2003, DELMARS MANUAL LAB D
  • [4] Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults
    Fagan, Anne M.
    Roe, Catherine M.
    Xiong, Chengjie
    Mintun, Mark A.
    Morris, John C.
    Holtzman, David M.
    [J]. ARCHIVES OF NEUROLOGY, 2007, 64 (03) : 343 - 349
  • [5] Adiponectin is independently associated with glycosylated haemoglobin
    Fernández-Real, JM
    Botas-Cervero, P
    López-Bermano, A
    Casamitjana, R
    Funahashi, T
    Delgado, E
    Kihara, S
    Ricart, W
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (02) : 201 - 205
  • [6] Physicians' views of the relative importance of thirty medical innovations
    Fuchs, VR
    Sox, HC
    [J]. HEALTH AFFAIRS, 2001, 20 (05) : 30 - 42
  • [7] Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
    Hansson, O
    Zetterberg, H
    Buchhave, P
    Londos, E
    Blennow, K
    Minthon, L
    [J]. LANCET NEUROLOGY, 2006, 5 (03) : 228 - 234
  • [8] A new era in psychiatric genetics?
    Insel, Thomas R.
    Lehner, Thomas
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (09) : 1017 - 1018
  • [9] Stroke risk profile predicts white matter hyperintensity volume - The Framingham Study
    Jeerakathil, T
    Wolf, PA
    Beiser, A
    Massaro, J
    Seshadri, S
    D'Agostino, RB
    DeCarli, C
    [J]. STROKE, 2004, 35 (08) : 1857 - 1861
  • [10] Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Kelloff, G
    Hoffman, JM
    Johnson, B
    Scher, HI
    Siegel, BA
    Cheng, EY
    Cheson, BD
    O'Shaughnessy, J
    Guyton, KZ
    Mankoff, DA
    Shankar, L
    Larson, SM
    Sigman, CC
    Schilsky, RL
    Sullivan, DC
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2785 - 2808